Biography
Professional Summary
Education & Certifications
- Medical Education: Georgetown University Internal Medicine Residency (2006) DC
- Internship, California pacific medical center, Internal medicine (2007)
- Residency: University of California Los Angeles (2008) CA
- Residency: Stanford University School of Medicine (2010) CA
- Fellowship: University of California at San Francisco School of Medicine (2013) CA
- Board Certification: United Council for Neurologic Subspecialties, Behavioral Neurology and Neuropsychiatry (2014)
- Board Certification: American Board of Psychiatry and Neurology, Neurology (2010)
Administrative Appointments
- Associate Vice Chair, Clinical Research, Department of Neurology (2021 - Present)
- Chief, Memory Disorders Division (2023 - Present)
- Director, Behavioral Neurology and Neuropsychiatry Fellowship (2015 - Present)
- Medical Director, Stanford Neurosciences Clinical Trials Group (2016 - Present)
Publications
-
Frontotemporal dementia due to C9ORF72 mutations Clinical and imaging features
Sha, S. J., Takada, L. T., Rankin, K. P., Yokoyama, J. S., Rutherford, N. J., Fong, J. C., … Boxer, A. L. (2012). Frontotemporal dementia due to C9ORF72 mutations Clinical and imaging features. NEUROLOGY, 79(10), 1002–11. -
Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease
Takada, L. T., & Sha, S. J. (2012). Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease. ALZHEIMERS RESEARCH & THERAPY, 4(5). -
Treatment implications of C9ORF72
Sha, S. J., & Boxer, A. (2012). Treatment implications of C9ORF72. ALZHEIMERS RESEARCH & THERAPY, 4(6). -
Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion
Khan, B. K., Yokoyama, J. S., Takada, L. T., Sha, S. J., Rutherford, N. J., Fong, J. C., … Miller, B. L. (2012). Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83(4), 358–364. -
Executive Functions in Premanifest Huntington's Disease
You, S. C., Geschwind, M. D., Sha, S. J., Apple, A., Satris, G., Wood, K. A., … Possin, K. L. (2014). Executive Functions in Premanifest Huntington's Disease. MOVEMENT DISORDERS, 29(3), 405–9. -
Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion
Lee, S. E., Khazenzon, A. M., Trujillo, A. J., Guo, C. C., Yokoyama, J. S., Sha, S. J., … Seeley, W. W. (2014). Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. BRAIN, 137, 3047–3060. -
Interrater reliability of the new criteria for behavioral variant frontotemporal dementia
LaMarre, A. K., Rascovsky, K., Bostrom, A., Toofanian, P., Wilkins, S., Sha, S. J., … Kramer, J. H. (2013). Interrater reliability of the new criteria for behavioral variant frontotemporal dementia. NEUROLOGY, 80(21), 1973–1977. -
Are frontotemporal lobar degeneration, progressive supranuclear palsy and corticobasal degeneration distinct diseases?
Sha, ron S., Hou, C., Viskontas, I. V., & Miller, B. L. (2006). Are frontotemporal lobar degeneration, progressive supranuclear palsy and corticobasal degeneration distinct diseases? NATURE CLINICAL PRACTICE NEUROLOGY, 2(12), 658–665. -
Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease.
Kramer, J. H., Jurik, J., Sha, S. J., Rankin, K. P., Rosen, H. J., Johnson, J. K., & Miller, B. L. (2003). Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cognitive and Behavioral Neurology , 16(4), 211–218. -
Quantitative 7T Phase Imaging in Premanifest Huntington Disease
Apple, A. C., Possin, K. L., Satris, G., JOHNSON, E., Lupo, J. M., Jakary, A., … Hess, C. P. (2014). Quantitative 7T Phase Imaging in Premanifest Huntington Disease. AMERICAN JOURNAL OF NEURORADIOLOGY, 35(9), 1707–1713. -
Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.
Sha, S. J., Ghosh, P. M., Lee, S. E., Corbetta-Rastelli, C., Jagust, W. J., Kornak, J., … Rabinovici, G. D. (2015). Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimer's Research & Therapy, 7(1), 8-? -
Early-onset Alzheimer's disease versus frontotemporal dementia: resolution with genetic diagnoses?
Sha, S. J., Khazenzon, A. M., Ghosh, P. M., Rankin, K. P., Pribadi, M., Coppola, G., … Lee, S. E. (2016). Early-onset Alzheimer's disease versus frontotemporal dementia: resolution with genetic diagnoses? Neurocase, 22(2), 161–67. -
Frontotemporal Dementia and Psychiatric Illness: Emerging Clinical and Biological Links in Gene Carriers
Block, N. R., Sha, S. J., Karydas, A. M., Fong, J. C., De May, M. G., Miller, B. L., & Rosen, H. J. (2016). Frontotemporal Dementia and Psychiatric Illness: Emerging Clinical and Biological Links in Gene Carriers. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 24(2), 107–16. -
Egocentric and allocentric visuospatial working memory in premotor Huntington's disease: A double dissociation with caudate and hippocampal volumes.
Possin, K. L., Kim, H., Geschwind, M. D., Moskowitz, T., Johnson, E. T., Sha, S. J., … Kramer, J. H. (2017). Egocentric and allocentric visuospatial working memory in premotor Huntington's disease: A double dissociation with caudate and hippocampal volumes. Neuropsychologia, 101, 57–64. -
An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations.
Sha, S. J., Miller, Z. A., Min, S.-W., Zhou, Y., Brown, J., Mitic, L. L., … Boxer, A. L. (2017). An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimer's & Dementia (New York, N. Y.), 3(4), 507–12. -
Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial.
Sha, S. J., Deutsch, G. K., Tian, L., Richardson, K., Coburn, M., Gaudioso, J. L., … Wyss-Coray, T. (2018). Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial. JAMA Neurology. -
Ultra-Low-Dose 18F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs.
Chen, K. T., Gong, E., de Carvalho Macruz, F. B., Xu, J., Boumis, A., Khalighi, M., … Zaharchuk, G. (2018). Ultra-Low-Dose 18F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs. Radiology, 180940. -
Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.
Peterson, B., Armstrong, M., Galasko, D., Galvin, J. E., Goldman, J., Irwin, D., … Boeve, B. (2019). Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research & Therapy, 11(1), 23. -
Positive Attitudes and Therapeutic Misconception Around Hypothetical Clinical Trial Participation in the Huntington's Disease Community.
Cotter, K., Siskind, C., Sha, S., & Hanson-Kahn, A. (2019). Positive Attitudes and Therapeutic Misconception Around Hypothetical Clinical Trial Participation in the Huntington's Disease Community. Journal of Huntington's Disease. -
Hippocampal and cortical mechanisms at retrieval explain variability in episodic remembering in older adults.
Trelle, A. N., Carr, V. A., Guerin, S. A., Thieu, M. K., Jayakumar, M., Guo, W., … Wagner, A. D. (2020). Hippocampal and cortical mechanisms at retrieval explain variability in episodic remembering in older adults. ELife, 9. -
Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases.
Mormino, E. C., Toueg, T. N., Azevedo, C., Castillo, J. B., Guo, W., Nadiadwala, A., … Chin, F. T. (2020). Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging. -
Visual Read Protocols for Clinicians Analyzing 18F-PI-2620 tau PET/MRI Images
Koran, M. E., Shams, S., Adams, P., Toueg, T., Azevedo, C., Hall, J., … Mormino, E. (2020). Visual Read Protocols for Clinicians Analyzing 18F-PI-2620 tau PET/MRI Images. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease.
Trelle, A. N., Carr, V. A., Wilson, E. N., Swarovski, M. S., Hunt, M. P., Toueg, T. N., … Mormino, E. C. (2021). Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease. Neurology. -
Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab.
Hall, J. N., Mormino, E., Ng, A., Boumis, A., Gaudioso, J. L., Davidzon, G. A., & Sha, S. J. (2021). Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab. JAMA Neurology. -
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.
Scott, G. D., Arnold, M. R., Beach, T. G., Gibbons, C. H., Kanthasamy, A. G., Lebovitz, R. M., … Irwin, D. J. (2021). Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 12, 805135. -
Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities-Reply.
Hall, J. N., & Sha, S. J. (2022). Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities-Reply. JAMA Neurology. -
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Wilson, E. N., Young, C. B., Ramos Benitez, J., Swarovski, M. S., Feinstein, I., Vandijck, M., … Andreasson, K. I. (2022). Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease. Alzheimer's Research & Therapy, 14(1), 172. -
Illusory responses across the Lewy body disease spectrum
Shahid, M., Rawls, A., Ramirez, V., Ryman, S., Santini, V., Yang, L., … Poston, K. (2022). Illusory responses across the Lewy body disease spectrum. MOVEMENT DISORDERS. WILEY. -
Prediction of neuropathologic lesions from clinical data.
Phongpreecha, T., Cholerton, B., Bhukari, S., Chang, A. L., De Francesco, D., Thuraiappah, M., … Montine, T. J. (2023). Prediction of neuropathologic lesions from clinical data. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Illusory Responses across the Lewy Body Disease Spectrum
Shahid, M., Rawls, A., Ramirez, V., Ryman, S., Santini, V. E., Yang, L., … Poston, K. L. (2023). Illusory Responses across the Lewy Body Disease Spectrum. ANNALS OF NEUROLOGY. -
The MVP or the tombstone: is tau the correct target to treat Alzheimer's disease?
Younes, K., & Sha, S. J. (2023). The MVP or the tombstone: is tau the correct target to treat Alzheimer's disease? Brain : a Journal of Neurology. -
Addition of Vision Impairment to a Life-Course Model of Potentially Modifiable Dementia Risk Factors in the US RESPONSE
Hall, J. N., & Sha, S. J. (2022). Addition of Vision Impairment to a Life-Course Model of Potentially Modifiable Dementia Risk Factors in the US RESPONSE. JAMA NEUROLOGY, 79(6), 623–626. -
Learning slopes in early-onset Alzheimer's disease.
Hammers, D. B., Nemes, S., Diedrich, T., Eloyan, A., Kirby, K., Aisen, P., … Apostolova, L. G. (2023). Learning slopes in early-onset Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection.
Hammers, D. B., Eloyan, A., Taurone, A., Thangarajah, M., Beckett, L., Gao, S., … Apostolova, L. G. (2023). Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort.
Polsinelli, A. J., Wonderlin, R. J., Hammers, D. B., Garcia, A. P., Eloyan, A., Taurone, A., … Apostolova, L. G. (2023). Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Research Priorities of Individuals and Caregivers With Lewy Body Dementia A Web-based Survey
Holden, S. K., Bedenfield, N., Taylor, A. S., Bayram, E., Schwilk, C., Fleisher, J., … Armstrong, M. J. (2023). Research Priorities of Individuals and Caregivers With Lewy Body Dementia A Web-based Survey. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 37(1), 50–58. -
Sex and APOE epsilon4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.
Nemes, S., Logan, P. E., Manchella, M. K., Mundada, N. S., La Joie, R., Polsinelli, A. J., … Apostolova, L. G. (2023). Sex and APOE epsilon4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Eloyan, A., Thangarajah, M., An, N., Borowski, B. J., Reddy, A. L., Aisen, P., … Vemuri, P. (2023). White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study.
Dage, J. L., Eloyan, A., Thangarajah, M., Hammers, D. B., Fagan, A. M., Gray, J. D., … Apostolova, L. G. (2023). Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Lewy Body Dementia: An Overview of Promising Therapeutics.
Skylar-Scott, I. A., & Sha, S. J. (2023). Lewy Body Dementia: An Overview of Promising Therapeutics. Current Neurology and Neuroscience Reports. -
Influence of amyloid and diagnostic syndrome on non-traditional memory scores in early-onset Alzheimer's disease.
Bushnell, J., Hammers, D. B., Aisen, P., Dage, J. L., Eloyan, A., Foroud, T., … Clark, D. G. (2023). Influence of amyloid and diagnostic syndrome on non-traditional memory scores in early-onset Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Cho, H., Mundada, N. S., Apostolova, L. G., Carrillo, M. C., Shankar, R., Amuiri, A. N., … Rabinovici, G. D. (2023). Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort.
Nudelman, K. N., Jackson, T., Rumbaugh, M., Eloyan, A., Abreu, M., Dage, J. L., … Apostolova, L. G. (2023). Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort.
Touroutoglou, A., Katsumi, Y., Brickhouse, M., Zaitsev, A., Eckbo, R., Aisen, P., … Dickerson, B. C. (2023). The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
Post-translational modifications linked to preclinical Alzheimer's disease-related pathological and cognitive changes.
Abiose, O., Rutledge, J., Moran-Losada, P., Belloy, M. E., Wilson, E. N., He, Z., … Mormino, E. C. (2023). Post-translational modifications linked to preclinical Alzheimer's disease-related pathological and cognitive changes. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. -
The Cerebellar Cognitive Affective/Schmahmann Syndrome Scale in Spinocerebellar Ataxias.
Selvadurai, L. P., Perlman, S. L., Ashizawa, T., Wilmot, G. R., Onyike, C. U., Rosenthal, L. S., … Schmahmann, J. D. (2024). The Cerebellar Cognitive Affective/Schmahmann Syndrome Scale in Spinocerebellar Ataxias. Cerebellum (London, England). -
Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation.
Johns, E., Vossler, H. A., Young, C. B., Carlson, M. L., Winer, J. R., Younes, K., … Mormino, E. C. (2024). Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation. Alzheimer's & Dementia : the Journal of the Alzheimer's Association.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
- AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
- Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
- Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
- A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
- The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
- Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
- Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
- 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
- A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
- A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
Practice Locations
Stanford Neuroscience Health Center Palo Alto, CA
Palo Alto, CAStanford Neuroscience Health Center
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereMemory Disorders Center in Palo Alto Palo Alto, CA
Palo Alto, CAMemory Disorders Center in Palo Alto
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(156 reviews)
View More
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records